1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Jul 2025
Admin
News Article

Astellas partners with the KISED for the operation of the “Partnership with Global Companies Programme

Overview

Astellas Pharma Inc., a global life sciences company, announced that it has agreed on a memorandum of understanding (MoU) with the Korea Institute of Startup and Entrepreneurship Development (KISED), an umbrella organization of the Ministry of SMEs and Startups, a Korean Government Agency, for the operation of the Partnership with Global Companies Programme, which aims to identify Korean drug-discovery startups and support their business growth and global expansion.

Terms of the MoU

Under the terms of the MoU, KISED will provide overall management and research funding for the Partnership with Global Companies Programme.
Astellas will provide Korean drug-discovery startups, which are selected together, with KISED with access to laboratory and office space at SakuLab-Tsukuba, located on the premises of the Astellas Tsukuba Research Center.
Startups residing in SakuLab-Tsukuba will not only receive support through consultations with Astellas experts in various fields, but will also be able to accelerate their drug discovery research by leveraging networks with fellow residents and Astellas researchers.

The collaboration for future

Through this programme, two Korean pharmaceutical and biotech startups—TCUBEiT Inc. (a next-generation T-cell-based immunotherapy developer) and AAVATAR Therapeutics (specializing in AAV viral vector engineering technology)—have been selected. They will begin full-scale collaboration by moving into SakuLab-Tsukuba.

Statement from Tadaaki Taniguchi: CRDO of Astellas

Tadaaki Taniguchi, M.D., Ph.D., chief research & development officer (CRDO) of Astellas, said: “We are very pleased to agree on a MoU with KISED for the Operation of the Partnership with Global Companies Programme. In today's world, where new drug discovery ideas and technologies are emerging one after another, Diverse perspectives, expertise and experiences are essential to turning innovative ideas and technologies into VALUE for patients.”
“Astellas is committed to fostering innovation in collaboration with startups by providing knowledge and expertise we have gained through our research and global network. We expect that the signing of this MoU will further strengthen and accelerate drug discovery research together with Korean startups, ultimately contributing to the creation of innovative medical solutions.”

Statement from Jong-pil Yoo: President of KISED

Jong-pil Yoo, president of KISED, said: “This agreement will serve as a significant opportunity to accelerate the global expansion of promising Korean startups in the bio and pharmaceutical sectors through strategic collaboration with Astellas, a global pharmaceutical company. In particular, as new drug development requires a high level of expertise and infrastructure, this programme—enabling startups to leverage Astellas' research assets and global network directly—is expected to provide substantial support for their growth. KISED will continue to strengthen its partnerships with global corporations to ensure that Korean startups can enhance their competitiveness in the global market.”

About Astellas

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients.
The company provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health.
The impact of this partnership on Astellas’ financial results for the fiscal year ending March 31, 2026, is expected to be minor.

About South Korean Ministry of SMEs

The Ministry of SMEs and Startups is a central government agency in South Korea, dedicated to enhancing the competitiveness and fostering innovation among small and medium-sized enterprises (SMEs) and venture businesses.
Initially established in 1996 as the Ministry of SMEs, it was rebranded in 2017 as the Ministry of SMEs and Startups to more accurately reflect its expanded focus and objectives.

About KISED

KISED carries out strategic initiatives aimed at advancing the startup ecosystem, enabling tailored and successful startups, securing sustainable future growth engines, and realizing creative and innovative smart management.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!